| Titre | | nb de chargement | |
|---|
| Immunogenicity and clinical activity of Tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: a randomized phase 2 study in recurrent or metastatic (R/M) anogenital cancers | | 6 | |
| Immunogenicity and clinical activity of Tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: a randomized phase 2 study in recurrent or metastatic (R/M) anogenital cancers | | 6 | |
| Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma | | 6 | |
| Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma | | 6 | |
| Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting | | 157 | |
| Transgene présente des données sur ses deux vaccins thérapeutiques contre le cancer à l'ASCO 2023 | | 179 | |
| Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001 in solid tumors | | 195 | |
| Transgene et BioInvent annoncent des résultats positifs pour l'essai de Phase Ia du virus oncolytique BT-001 dans le traitement des tumeurs solides | | 1251 | |
| Transgene provides business update and Q1 2023 financial position | | 1574 | |
| Transgene fait un point sur son activité et publie sa situation financière au premier trimestre 2023 | | 1276 | |
| Transgene - First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer | | 924 | |
| Transgene - Premier patient traité dans l'essai de Phase I évaluant TG6050, un virus oncolytique innovant armé avec de l'IL-12, dans le cancer du poumon non à petites cellules | | 892 | |
| Transgene's Combined General Meeting of May 5, 2023 | | 356 | |
| Assemblée Générale Mixte de Transgene du 5 mai 2023 | | 390 | |
| Nouveau leadership pour accélérer le développement du portefeuille dimmunothérapies innovantes | | 6 | |
| New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio | | 6 | |
| Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio | | 269 | |
| Transgene annonce un nouveau leadership pour accélérer le développement de son portefeuille dimmunothérapies innovantes | | 322 | |
| New Data Showing that Transgene and NEC's Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023 | | 2798 | |
| Présentation à l'AACR de nouvelles données montrant que le vaccin thérapeutique individualisé TG4050 de Transgene et NEC induit des réponses immunitaires fortes et spécifiques contre les tumeurs | | 1632 | |
| PoxSTG, a novel chimeric poxvirus with improved oncolytic potency | | 6 | |
| PoxSTG, a novel chimeric poxvirus with improved oncolytic potency | | 6 | |
| Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators | | 6 | |
| Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators | | 6 | |
| Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer | | 6 | |
| Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer | | 6 | |
| A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) human papilloma virus (HPV)-16 positive anogenital cancers | | 6 | |
| A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) human papilloma virus (HPV)-16 positive anogenital cancers | | 6 | |
| Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer | | 6 | |
| Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer | | 6 | |
| Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy | | 6 | |
| Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy | | 6 | |
| Extracellular vesicles (EV): mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses | | 6 | |
| Extracellular vesicles (EV): mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses | | 6 | |
| TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses | | 6 | |
| TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses | | 6 | |
| Transgene - Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR | | 381 | |
| Présentation à l'AACR de résultats précliniques montrant que TG6050, un virus oncolytique innovant, induit une régression tumorale grâce à l'activation des réponses immunitaires innées et adaptatives | | 653 | |
| Transgene's Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director | | 657 | |
| Le conseil d'administration de Transgene propose la nomination de Carol Stuckley, en tant que nouvelle administratrice indépendante | | 400 | |
| Availability of Preparatory Documents for the Combined General Meeting of May 5, 2023 | | 2072 | |
| Mise à disposition des documents préparatoires à l'Assemblée générale du 5 mai 2023 | | 553 | |
| annonce kol event | | 6 | |
| annonceR&D | | 6 | |
| 2022 Full-year results and business update | | 6 | |
| Résultats annuels 2022 | | 6 | |
| Availability of Transgenes 2022 Universal Registration Document | | 1439 | |
| Mise à disposition du document d'enregistrement universel 2022 | | 336 | |
| Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers | | 2431 | |
| Transgene organise un webinaire sur TG4050, un vaccin thérapeutique individualisé contre les cancers de la tête et du cou HPV négatifs | | 934 | |
| Scientific advisors | | 7 | |
| Conseillers scientifiques | | 7 | |
| Scientific advisors | | 7 | |
| Conseillers scientifiques | | 7 | |
| Pedro Romero, MD | | 7 | |
| Pedro Romero, MD | | 7 | |
| John C. Bell, PhD | | 7 | |
| John C. Bell, PhD | | 7 | |
| Transgene Announces Upcoming Investor Meetings | | 558 | |
| Transgene annonce ses prochaines rencontres avec les investisseurs | | 327 | |
| Positive data on key clinical candidates delivered in 2022 - Promising outlook for 2023 as industry interest in therapeutic cancer vaccines and oncolytic viruses gains significant momentum | | 3622 | |
| Les données positives générées en 2022 avec les principaux candidats cliniques confortent les perspectives de Transgene pour 2023, dans un contexte porteur pour les vaccins thérapeutiques contre le cancer et les virus oncolytiques | | 2607 | |
| Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023 | | 3585 | |
| Transgene présentera plusieurs posters soulignant le potentiel de son portefeuille d'immunothérapies à l'AACR 2023 | | 4501 | |
| Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors | | 1065 | |
| Transgene nomme John C. Bell et Pedro Romero en tant que Conseillers Scientifiques | | 432 | |
| TG6050 | | 94 | |
| TG6050 | | 94 | |
| produits : TG6050 - en | | 94 | |
| produits : TG6050 | | 94 | |
| Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration | | 12668 | |
| Transgene reçoit l'autorisation de lancer un essai de Phase I avec TG6050, un virus oncolytique innovant armé avec de l'IL-12 et administré par voie intraveineuse | | 8099 | |
| Transgene announces Financial Calendar for 2023 | | 6711 | |
| Transgene présente son calendrier de communication financière pour 2023 | | 7277 | |
| Degroof Petercams Virtual Healthcare Conference 27 janvier 2023 | | 12543 | |
| LifeSci Advisors Corporate Access Event - San Francisco, USA - January 9 to 12, 2022 | | 12543 | |
| LifeSci Advisors Corporate Access Event San Francisco, États-Unis - 9 au 12 janvier 2022 | | 12543 | |
| Degroof Petercams Virtual Healthcare Conference January 27, 2023 | | 12543 | |
| BIO CEO & Investor Forum (New York) 6 au 9 février 2023 | | 12543 | |
| 26th ODDO BHF Forum - Virtual - January 9 and 10, 2023 | | 12543 | |
| 26e Forum ODDO BHF - Virtuel - 9 et 10 janvier 2023 | | 12543 | |
| Invest Securities Biomed Forum - January 24, 2023 | | 12543 | |
| Invest Securities Biomed Forum - 24 janvier 2023 | | 12543 | |
| BIO CEO & Investor Forum (New York) - February 6 to 9, 2023 | | 12543 | |
| Transgene Announces Upcoming Investor Meetings | | 16767 | |
| Transgene annonce ses prochaines rencontres avec les investisseurs | | 13234 | |
| __cf_bm | | 12543 | |
| vuid | | 12543 | |
| _pk_ses.1.9651 | | 12543 | |
| _pk_id.1.9651 | | 12543 | |
| JSESSIONID | | 12543 | |
| CookieLawInfoConsent | | 12543 | |
| viewed_cookie_policy | | 12543 | |
| cookielawinfo-checkbox-fonctionnels | | 12543 | |
| cookielawinfo-checkbox-cookies-externes | | 12543 | |
| cookielawinfo-checkbox-analytique | | 12543 | |
| cookielawinfo-checkbox-essentiels | | 12543 | |
| Transgene and BioInvent joint paper on BT-001 wins JITC Best Oncolytic and Local Immunotherapy Paper Award for 2022 | | 20386 | |
| Transgene et BioInvent remportent le prix du Meilleur Article dans la catégorie Immunothérapie oncolytique et locale décerné par le JITC, pour leurs travaux sur BT-001 | | 14721 | |
| Politique de confidentialité | | 13812 | |
| | 13812 | |
| | 13812 | |
| | 13812 | |
| Cookie policy | | 13812 | |
| privacy policy | | 13812 | |
| POLITIQUE DE CONFIDENTIALITE | | 13812 | |
| PRIVACY POLICY | | 13812 | |
| Transgene reports business update and Q3 2022 financial position | | 14541 | |
| Transgene fait le point sur ses activités et sa situation financière au troisième trimestre 2022 | | 14473 | |
| Politique Cookies de Transgene | | 13812 | |
| COOKIE POLICY | | 13812 | |
| annoncegb4001 | | 13813 | |
| annonce4001 | | 13813 | |
| Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers | | 14489 | |
| Transgene annonce le résultat positif de l'analyse intermédiaire de l'essai de Phase II évaluant TG4001 + Avelumab vs Avelumab seul dans les cancers anogénitaux HPV-positifs | | 16876 | |
| Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas | | 21748 | |
| Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas | | 21748 | |
| R&D Day: Presentations to Highlight Transgene's Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data | | 44447 | |
| Journée R&D : présentations sur le positionnement compétitif de Transgene, sa capacité à concevoir des immunothérapies nouvelles pour les patients atteints de cancer et sur des données cliniques actualisées | | 22843 | |
| annonceR&D | | 24483 | |
| annonceR&D | | 24483 | |
| Transgene R&D Day (Paris, France) | | 26291 | |
| Journée R&D de Transgene Paris | | 26291 | |
| Transgene Confirms the Potential of the Intravenous Route of its Invir.IO Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022 | | 29055 | |
| Les données de Phase I de TG6002 présentées à lESMO 2022 confirment le potentiel des virus oncolytiques Invir.IO® de Transgene administrés par voie intraveineuse pour traiter les tumeurs solides | | 30311 | |
| Positive Readouts for Transgene's Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022 | | 27161 | |
| Données cliniques positives pour les candidats-médicaments issus des deux plateformes innovantes de Transgene - Nouveaux résultats attendus au second semestre 2022 | | 27444 | |
| 2022 Half-year results and business update | | 29026 | |
| Résultats financiers du 1er semestre 2022 et point sur lactivité | | 29026 | |
| 2021 Full-year results and business update | | 29026 | |
| Résultats annuels 2021 et point sur lactivité | | 29026 | |
| Transgene announces Upcoming Investor Meetings | | 35925 | |
| Transgene annonce ses prochaines rencontres avec les investisseurs | | 33145 | |
| decompte twitter | | 35434 | |
| Transgene and BioInvent announce clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA® | | 47860 | |
| Transgene et BioInvent annoncent la conclusion d'un accord avec MSD de collaboration clinique et d'approvisionnement pour évaluer BT-001 en combinaison avec KEYTRUDA® | | 41656 | |
| Transgene and BioInvent announce positive progress for BT-001 | | 47728 | |
| Transgene et BioInvent présentent les avancées positives de BT-001 | | 39482 | |
| TG4050 | | 41200 | |
| TG4050 | | 41200 | |
| annonce TG4050en | | 41200 | |
| annonce TG4050 | | 41200 | |
| Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022 | | 42569 | |
| Transgene a présenté de nouvelles données de Phase I de TG4050 au congrès de l'ASCO 2022 | | 43585 | |
| Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC) | | 42524 | |
| Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC) | | 42524 | |
| Carol Stuckley | | 42524 | |
| Carol Stuckley | | 42524 | |
| Prof. Jean-Yves Blay? | | 42524 | |
| Pr Jean-Yves Blay | | 42524 | |
